FDA Approves Twyneo for the Topical Treatment of Acne Vulgaris

Sol-Gel Technologies, a pharmaceutical company that specializes in dermatological treatments, has announced that their product, Twyneo®, has received approval from the Food and Drug Administration (FDA) for the topical treatment of acne vulgaris in patients aged 9 and older. The cream contains tretinoin 0.1% and benzoyl peroxide 3%.

DelRicht’s Role, Perspective, and Lead Investigators

The clinical trial for Twyneo® involved the participation of DelRicht Research, a research organization located in New Orleans, LA. Dr. Sarah Jackson and Dr. Deirdre Hooper, both of whom attended medical school at LSU Health, were the principal investigators in the trial. One of the challenges in the study was the need to recruit a diverse patient population.

“We know that acne can affect people of all ages and skin types, so it was important for us to have a diverse patient population in the study to ensure that Twyneo® would be effective for a wide range of patients,” said Tyler Hastings, Managing Partner of DelRicht Research.

The approval of Twyneo® is a significant milestone in dermatological medicine. It represents a new option for patients with acne vulgaris and offers hope for those who have not responded to other treatments.

“The approval of Twyneo® is an important step forward in the treatment of acne vulgaris,” said Rachel Hastings, Managing Partner of DelRicht Research. “It’s exciting to see a new treatment option that can help patients achieve clear skin.”

“The approval of Twyneo® is an important step forward in the treatment of acne vulgaris,” said Rachel Hastings, Managing Partner of DelRicht Research. “It’s exciting to see a new treatment option that can help patients achieve clear skin.”

— Rachel Hastings, Managing Partner at DelRicht Research

How Twyneo® Works

Twyneo® works by combining two active ingredients, tretinoin and benzoyl peroxide, which have complementary mechanisms of action. Tretinoin helps to regulate cell turnover and prevent the formation of comedones, while benzoyl peroxide works to reduce inflammation and kill the bacteria that cause acne.

The approval of Twyneo® is also significant because it offers a new option for young patients with acne. Many current treatments for acne have limitations or side effects that make them unsuitable for use in children.

Advancing Dermatological Medicine

Overall, the approval of Twyneo® represents a significant advancement in dermatological medicine. It offers a new option for patients with acne vulgaris, including those who have not responded to other treatments. It also provides a new treatment option for young patients with acne and offers hope for those who have struggled to find effective treatments.

“We are proud to have played a role in the clinical trial for Twyneo® and to have helped bring this important new treatment option to patients,” said Tyler Hastings. “At DelRicht Research, we remain committed to advancing medical research and finding new treatments for the patients who need them.”

“We are proud to have played a role in the clinical trial for Twyneo® and to have helped bring this important new treatment option to patients,” said Tyler Hastings. “At DelRicht Research, we remain committed to advancing medical research and finding new treatments for the patients who need them.”

— Tyler Hastings, Managing Partner at DelRicht Research